GRM5 and fragile X syndrome: Negative modulators of the mGluR5 receptor are capable of producing morphological and behavioural changes after a single dose.21, 22 Accordingly we felt it most appropriate to examine the effects of fenobam in patients with FXS with a single dose in this first clinical trial of an mGluR5 antagonist.